UNSPSC 51145000: Stimulant or anorexiant indoles

This classification denotes substances derived from benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, substances called indoles, that tend to increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT INDOLES.

UNSPSC 51145000 Stimulant or anorexiant indoles is a Class code under which state and local governments procure pharmaceutical products, though recent activity shows significant misalignment between the code's nominal scope and actual solicitation content. The three recent opportunities posted under this code involve naloxone (an opioid antagonist, not a stimulant), generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs — none of which fit the indole stimulant or anorexiant classification. The work being solicited includes annual supply of naloxone units and drug deactivation systems for community health distribution, manufacturer participation in multi-state cooperative pharmaceutical contracts serving state and local health systems, and exploratory vendor capability assessment for direct pharmaceutical contracting models outside traditional pharmacy benefit manager channels.

Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance with participation from Oregon and other jurisdictions). The geographic footprint includes Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida (due July 26, 2023); the Texas HHS Commission's RFI regarding direct-to-manufacturer prescription program capabilities (posted April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple participating jurisdictions with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date. The code shows limited recent activity and appears poorly matched to actual pharmaceutical procurement needs — the mismatch suggests either systematic miscoding in state and local procurement systems or that this code is not actively used for its intended scope.